Pierre Beaulieu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pierre Beaulieu has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
Julie Desroches
Department of Anesthesiology, CHUM, Montreal, Canada
4 shared publicationsChantal Lambert
2 shared publicationsJ Desroches
Department of Pharmacology, Université de Montréal-CHUM, Montréal, Quebec, Canada
2 shared publicationsJ Guindon
Department of Pharmacology, Université de Montréal—CHUM Montréal, Quebec, Canada
2 shared publications- Jean-François Bouchard
Université de Montréal, École d’Optométrie, Montreal, Quebec, Canada
2 shared publications - Philippe Richebé
Maisonneuve-Rosemont Hospital Research Center, Hôpital Maisonneuve-Rosemont, Montreal, Canada
2 shared publications
Latest Publications
- Open Access
Pulmonary complications and mortality among COVID-19 patients undergoing a surgery: a multicentre cohort study
Objectives Our primary objective was to assess the association between symptoms at the time of surgery and postoperative pulmonary complications and mortality in patients with COVID-19. Our secondary objective was to compare postoperative outcomes between patients who had recovered from COVID-19 and asymptomatic patients and explore the effect of the time elapsed between infection and surgery in the former. Our hypotheses were that symptomatic patients had a higher risk of pulmonary complications, whereas patients who had recovered from the infection would exhibit outcomes similar to those of asymptomatic patients. Background Managing COVID-19-positive patients requiring surgery is complex due to perceived heightened perioperative risks. However, Canadian data in this context remains scarce. Design To address this gap, we conducted a multicentre observational cohort study. Setting Across seven hospitals in the province of Québec, the Canadian province was most affected during the initial waves of the pandemic. Participants We included adult surgical patients with either active COVID-19 at the time of surgery or those who had recovered from the disease, from March 22, 2020 to April 30, 2021. Outcomes We evaluated the association between symptoms or recovery time and postoperative pulmonary complications and hospital mortality using multivariable logistic regression and Cox models. The primary outcome was a composite of any postoperative pulmonary complication (atelectasis, pneumonia, acute respiratory distress syndrome and pneumothorax). Our secondary outcome was hospital mortality, assessed from the date of surgery up to hospital discharge. Results We included 105 patients with an active infection (47 were symptomatic and 58 were asymptomatic) at the time of surgery and 206 who had recovered from COVID-19 prior to surgery in seven hospitals. Among patients with an active infection, those who were symptomatic had a higher risk of pulmonary complications (OR 3.19, 95% CI 1.12 to 9.68, p=0.03) and hospital mortality (HR 3.67, 95% CI 1.19 to 11.32, p=0.02). We did not observe any significant effect of the duration of recovery prior to surgery on patients who had recovered from their infection. Their postoperative outcomes were also similar to those observed in asymptomatic patients. Interpretation Symptomatic status should be considered in the decision to proceed with surgery in COVID-19-positive patients. Our results may help optimise surgical care in this patient population. Study registration ClinicalTrials.gov Identifier: NCT04458337 registration date: 7 July 2020.
Open AccessPulmonary complications and mortality among COVID-19 patients undergoing a surgery: a multicentre cohort study
Objectives Our primary objective was to assess the association between symptoms at the time of surgery and postoperative pulmonary complications and mortality in patients with COVID-19. Our secondary objective was to compare postoperative outcomes between patients who had recovered from COVID-19 and asymptomatic patients and explore the effect of the time elapsed between infection and surgery in the former. Our hypotheses were that symptomatic patients had a higher risk of pulmonary complications, whereas patients who had recovered from the infection would exhibit outcomes similar to those of asymptomatic patients. Background Managing COVID-19-positive patients requiring surgery is complex due to perceived heightened perioperative risks. However, Canadian data in this context remains scarce. Design To address this gap, we conducted a multicentre observational cohort study. Setting Across seven hospitals in the province of Québec, the Canadian province was most affected during the initial waves of the pandemic. Participants We included adult surgical patients with either active COVID-19 at the time of surgery or those who had recovered from the disease, from March 22, 2020 to April 30, 2021. Outcomes We evaluated the association between symptoms or recovery time and postoperative pulmonary complications and hospital mortality using multivariable logistic regression and Cox models. The primary outcome was a composite of any postoperative pulmonary complication (atelectasis, pneumonia, acute respiratory distress syndrome and pneumothorax). Our secondary outcome was hospital mortality, assessed from the date of surgery up to hospital discharge. Results We included 105 patients with an active infection (47 were symptomatic and 58 were asymptomatic) at the time of surgery and 206 who had recovered from COVID-19 prior to surgery in seven hospitals. Among patients with an active infection, those who were symptomatic had a higher risk of pulmonary complications (OR 3.19, 95% CI 1.12 to 9.68, p=0.03) and hospital mortality (HR 3.67, 95% CI 1.19 to 11.32, p=0.02). We did not observe any significant effect of the duration of recovery prior to surgery on patients who had recovered from their infection. Their postoperative outcomes were also similar to those observed in asymptomatic patients. Interpretation Symptomatic status should be considered in the decision to proceed with surgery in COVID-19-positive patients. Our results may help optimise surgical care in this patient population. Study registration ClinicalTrials.gov Identifier: NCT04458337 registration date: 7 July 2020.
- 24 February 2023
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 70 (5) , 842-850
Efficacy of a propofol bolus against placebo to prevent cough at emergence from general anesthesia with desflurane: a randomized controlled trial
Purpose Emergence from anesthesia is a critical period and cough can result in adverse effects. Propofol inhibits airway reflexes and when infused it reduces cough more than inhalation anesthesia does. We evaluated the effect of a propofol bolus given at emergence on the incidence of coughing following a desflurane-based anesthesia. Methods One hundred and fifty-four patients scheduled for elective surgery were prospectively randomized to propofol (0.5 mg·kg−1) or normal saline (NS) administered at the end of the surgery at 1 minimum alveolar concentration (MAC) of desflurane. A “no touch” emergence technique was used until extubation. The primary outcome was the incidence of cough at the discontinuation of desflurane (T0) and reaching a MAC adjusted for age (MACage) of 0.15. Secondary outcomes included incidence and severity of cough until five minutes postextubation (T0–T5), time to extubation, nausea and vomiting, sedation, hemodynamic variations, postoperative hypoventilation, hypoxemia, and sore throat. Results We could not draw inferences on the incidence of cough between T0 and MACage of 0.15 because only 27/68 (40%) patients in the NS group and 13/73 (18%) patients in the propofol group regained consciousness before reaching a MACage of 0.15. There were no significant differences between the groups in coughing incidence and severity between T0 and T5 (NS group, 57/68 [84%] vs propofol group, 70/73 [96%] ). The mean time to extubation in the propofol group was prolonged by 3 min 27 sec (95% confidence interval, 1 min 7 sec to 4 min 47 sec; P < 0.001) and more vasopressors were used at emergence (P = 0.02). The incidence of respiratory complications, nausea and vomiting, agitation, and sedation were not different between groups. Conclusion In the present trial, a propofol bolus administered at emergence did not reduce the incidence of cough occurring between T0 and T5 following a desflurane-based general anesthesia compared with placebo. Trial registration ClinicalTrials.gov (NCT02932397); registered 13 October 2016.
- 24 February 2023
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 70 (5) , 842-850
Efficacy of a propofol bolus against placebo to prevent cough at emergence from general anesthesia with desflurane: a randomized controlled trial
Purpose Emergence from anesthesia is a critical period and cough can result in adverse effects. Propofol inhibits airway reflexes and when infused it reduces cough more than inhalation anesthesia does. We evaluated the effect of a propofol bolus given at emergence on the incidence of coughing following a desflurane-based anesthesia. Methods One hundred and fifty-four patients scheduled for elective surgery were prospectively randomized to propofol (0.5 mg·kg−1) or normal saline (NS) administered at the end of the surgery at 1 minimum alveolar concentration (MAC) of desflurane. A “no touch” emergence technique was used until extubation. The primary outcome was the incidence of cough at the discontinuation of desflurane (T0) and reaching a MAC adjusted for age (MACage) of 0.15. Secondary outcomes included incidence and severity of cough until five minutes postextubation (T0–T5), time to extubation, nausea and vomiting, sedation, hemodynamic variations, postoperative hypoventilation, hypoxemia, and sore throat. Results We could not draw inferences on the incidence of cough between T0 and MACage of 0.15 because only 27/68 (40%) patients in the NS group and 13/73 (18%) patients in the propofol group regained consciousness before reaching a MACage of 0.15. There were no significant differences between the groups in coughing incidence and severity between T0 and T5 (NS group, 57/68 [84%] vs propofol group, 70/73 [96%] ). The mean time to extubation in the propofol group was prolonged by 3 min 27 sec (95% confidence interval, 1 min 7 sec to 4 min 47 sec; P < 0.001) and more vasopressors were used at emergence (P = 0.02). The incidence of respiratory complications, nausea and vomiting, agitation, and sedation were not different between groups. Conclusion In the present trial, a propofol bolus administered at emergence did not reduce the incidence of cough occurring between T0 and T5 following a desflurane-based general anesthesia compared with placebo. Trial registration ClinicalTrials.gov (NCT02932397); registered 13 October 2016.
- 22 September 2021
- Published by JLE in Douleur et Analgésie
- Vol. 34 (3) , 179-187
Cannabis thérapeutique : l’expérience canadienne
Le système cannabinoïde est un ensemble pharmacologique mieux connu aujourd’hui qui pourrait offrir par sa modulation des avenues thérapeutiques intéressantes dans le futur. Au niveau canadien, l’utilisation du cannabis médical a fait l’objet d’une première réglementation mise en place en juillet 2001 suivie de plusieurs autres, la dernière datant de 2016 et concerne le règlement sur l’accès au cannabis à des fins médicales. Au niveau provincial, différents produits du cannabis sont proposés par les producteurs canadiens autorisés par Santé Canada, et leur nombre a récemment dépassé 500. Le cannabis médical « pharmaceutique » est disponible au Canada et peut être prescrit à des patients, notamment le nabiximols et la nabilone. Par ailleurs, une initiative du Collège des médecins du Québec a permis le recrutement de 3 002 patients entre mai 2015 et octobre 2018 afin d’établir un registre (registre Cannabis Québec) où le cannabis a été prescrit pour diverses indications thérapeutiques et sous différentes formes. La légalisation du cannabis au Canada en octobre 2018 ajoute une certaine complexité dans la distinction entre cannabis médical et cannabis récréatif, ce dernier étant en vente libre à la Société québécoise du cannabis. Néanmoins, le cannabis n’est pas encore considéré comme un médicament, et ses indications thérapeutiques sont rares ; le cannabis n’est pas en première ligne de traitement. Les effets indésirables sont fréquents, et le patient doit être suivi régulièrement et les posologies adaptées en fonction de la tolérance. Des études cliniques sont encore nécessaires afin de préciser les indications thérapeutiques du cannabis.
- 22 September 2021
- Published by JLE in Douleur et Analgésie
- Vol. 34 (3) , 179-187
Cannabis thérapeutique : l’expérience canadienne
Le système cannabinoïde est un ensemble pharmacologique mieux connu aujourd’hui qui pourrait offrir par sa modulation des avenues thérapeutiques intéressantes dans le futur. Au niveau canadien, l’utilisation du cannabis médical a fait l’objet d’une première réglementation mise en place en juillet 2001 suivie de plusieurs autres, la dernière datant de 2016 et concerne le règlement sur l’accès au cannabis à des fins médicales. Au niveau provincial, différents produits du cannabis sont proposés par les producteurs canadiens autorisés par Santé Canada, et leur nombre a récemment dépassé 500. Le cannabis médical « pharmaceutique » est disponible au Canada et peut être prescrit à des patients, notamment le nabiximols et la nabilone. Par ailleurs, une initiative du Collège des médecins du Québec a permis le recrutement de 3 002 patients entre mai 2015 et octobre 2018 afin d’établir un registre (registre Cannabis Québec) où le cannabis a été prescrit pour diverses indications thérapeutiques et sous différentes formes. La légalisation du cannabis au Canada en octobre 2018 ajoute une certaine complexité dans la distinction entre cannabis médical et cannabis récréatif, ce dernier étant en vente libre à la Société québécoise du cannabis. Néanmoins, le cannabis n’est pas encore considéré comme un médicament, et ses indications thérapeutiques sont rares ; le cannabis n’est pas en première ligne de traitement. Les effets indésirables sont fréquents, et le patient doit être suivi régulièrement et les posologies adaptées en fonction de la tolérance. Des études cliniques sont encore nécessaires afin de préciser les indications thérapeutiques du cannabis.
- 2 October 2018
- Published by JSTOR
- p. 10
Avant-propos de la première édition
- 2 October 2018
- Published by JSTOR
- p. 605-626
Pharmacologie en gastroentérologie
- Open Access
- 18 July 2018
- Published by Springer Nature in Systematic Reviews
- Vol. 7 (1) , 1-11
Relative frequency and risk factors for long-term opioid therapy following surgery and trauma among adults: a systematic review protocol
When patients have been on opioid therapy for more than 90 days, more than half of them continue using opioids years later. Knowing that long-term opioid consumption could lead to harmful side effects including misuse, abuse, and addiction, it is important to understand the risks of transitioning to prolonged opioid therapy to reduce its occurrence. Perioperative and trauma contexts are ideal models commonly used to study such transition. Long-term use of opioids might be associated with transformation of acute pain to chronic, which might be an example of a risk factor. The objectives of this knowledge synthesis are to examine the relative frequency and the risk factors for transitioning to long-term opioid therapy among patients who have undergone a surgical procedure or experienced a trauma. The proposed study methodology is based on Preferred ReportIng Systematic Reviews and Meta-Analysis Protocols (PRISMA-P) statements on the conduct of systematic review and meta-analysis, the MOOSE Guidelines for Meta-Analyses and Systematic Reviews of Observational Studies, and the Cochrane Handbook for Systematic Review of Interventions. A systematic literature search will include multiple databases: Cochrane Central, EMBASE, MEDLINE, PsycINFO, CINHAL, PubMed, and the grey literature. We will identify studies related to opioid use beyond acute/subacute pain control after surgery or trauma. Two of the reviewers will screen all retrieved articles for eligibility and data extraction then critically appraise all identified studies. We will compile a narrative synthesis of all results and conduct a meta-analysis when feasible. As available data permits, we will perform a subgroup analysis of vulnerable populations. This systematic review will contribute to the prevention and harm reduction strategies associated with prescription opioids by identifying risk factors leading to the unwarranted long-term opioid therapy. The identification of common risk factors for long-term opioid therapy will help to orient further research on pain management as well as offer key therapeutic targets for the development of strategies to prevent prolonged opioid use. This protocol was registered in PROSPERO on March 2, 2018; registration number CRD42012018089907 .
- 18 July 2018
- Published by Springer Nature in Systematic Reviews
- Vol. 7 (1) , 1-11
Open AccessRelative frequency and risk factors for long-term opioid therapy following surgery and trauma among adults: a systematic review protocol
When patients have been on opioid therapy for more than 90 days, more than half of them continue using opioids years later. Knowing that long-term opioid consumption could lead to harmful side effects including misuse, abuse, and addiction, it is important to understand the risks of transitioning to prolonged opioid therapy to reduce its occurrence. Perioperative and trauma contexts are ideal models commonly used to study such transition. Long-term use of opioids might be associated with transformation of acute pain to chronic, which might be an example of a risk factor. The objectives of this knowledge synthesis are to examine the relative frequency and the risk factors for transitioning to long-term opioid therapy among patients who have undergone a surgical procedure or experienced a trauma. The proposed study methodology is based on Preferred ReportIng Systematic Reviews and Meta-Analysis Protocols (PRISMA-P) statements on the conduct of systematic review and meta-analysis, the MOOSE Guidelines for Meta-Analyses and Systematic Reviews of Observational Studies, and the Cochrane Handbook for Systematic Review of Interventions. A systematic literature search will include multiple databases: Cochrane Central, EMBASE, MEDLINE, PsycINFO, CINHAL, PubMed, and the grey literature. We will identify studies related to opioid use beyond acute/subacute pain control after surgery or trauma. Two of the reviewers will screen all retrieved articles for eligibility and data extraction then critically appraise all identified studies. We will compile a narrative synthesis of all results and conduct a meta-analysis when feasible. As available data permits, we will perform a subgroup analysis of vulnerable populations. This systematic review will contribute to the prevention and harm reduction strategies associated with prescription opioids by identifying risk factors leading to the unwarranted long-term opioid therapy. The identification of common risk factors for long-term opioid therapy will help to orient further research on pain management as well as offer key therapeutic targets for the development of strategies to prevent prolonged opioid use. This protocol was registered in PROSPERO on March 2, 2018; registration number CRD42012018089907 .
- 27 September 2017
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 64 (12) , 1236-1264
Anesthetic implications of recreational drug use
As the use of recreational drugs increases, the likelihood of an anesthesiologist perioperatively encountering patients using or addicted to these drugs will also increase.
- 27 September 2017
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 64 (12) , 1236-1264
Anesthetic implications of recreational drug use
As the use of recreational drugs increases, the likelihood of an anesthesiologist perioperatively encountering patients using or addicted to these drugs will also increase.
- 10 August 2017
- Published by Springer Nature
- p. 317-339
The Addicted Patient
- 2 March 2016
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 63 (6) , 725-730
Postoperative awake paralysis in the intensive care unit after cardiac surgery due to residual neuromuscular blockade: a case report and prospective observational study
We report a case of awake paralysis due to residual neuromuscular blockade (NMB) in the intensive care unit (ICU) in a patient following fast-track cardiac surgery. As a result of this case, we performed a prospective quality assurance audit to investigate the incidence of residual paralysis in the ICU in a similar population of cardiac surgery patients. A 73-yr-old woman (69 kg) underwent coronary artery bypass surgery under anesthesia induced with intravenous sufentanil 25 µg, midazolam 5 mg, ketamine 25 mg, and rocuronium 100 mg (followed by two additional 50-mg doses during surgery) and maintained with sevoflurane. Postoperatively in the ICU, the patient was initially sedated with propofol (50 mg·hr−1) but failed to awaken 90 min after its cessation. As train-of-four neurostimulation showed residual paralysis, she was re-sedated. Neostigmine 3 mg and glycopyrrolate 0.6 mg were administered, and she was extubated 30 min later. During this episode of residual paralysis, the patient was conscious and reported explicit memory of the events. She was discharged on day 7 without psychological distress related to her postoperative awake paralysis. We subsequently performed a prospective audit in 50 consecutive patients to determine the timing of NMB dosing and to quantify the incidence of residual paralysis after fast-track cardiac surgery. Of the 50 patients studied, 24 (48%) had received an NMB during the last hour of surgery and 33 (66%) had evidence of residual paralysis during the immediate postoperative period. Postoperative residual paralysis after fast-track cardiac surgery was common in our institution and likely contributed to the reported case of postoperative awake paralysis. We suggest that an NMB not be administered after intubation in fast-track patients. If given, however, it must be well communicated to the ICU team upon ICU admission. We further recommend routine assessment of neuromuscular function before sedation is weaned prior to extubation.
- 2 March 2016
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 63 (6) , 725-730
Postoperative awake paralysis in the intensive care unit after cardiac surgery due to residual neuromuscular blockade: a case report and prospective observational study
We report a case of awake paralysis due to residual neuromuscular blockade (NMB) in the intensive care unit (ICU) in a patient following fast-track cardiac surgery. As a result of this case, we performed a prospective quality assurance audit to investigate the incidence of residual paralysis in the ICU in a similar population of cardiac surgery patients. A 73-yr-old woman (69 kg) underwent coronary artery bypass surgery under anesthesia induced with intravenous sufentanil 25 µg, midazolam 5 mg, ketamine 25 mg, and rocuronium 100 mg (followed by two additional 50-mg doses during surgery) and maintained with sevoflurane. Postoperatively in the ICU, the patient was initially sedated with propofol (50 mg·hr−1) but failed to awaken 90 min after its cessation. As train-of-four neurostimulation showed residual paralysis, she was re-sedated. Neostigmine 3 mg and glycopyrrolate 0.6 mg were administered, and she was extubated 30 min later. During this episode of residual paralysis, the patient was conscious and reported explicit memory of the events. She was discharged on day 7 without psychological distress related to her postoperative awake paralysis. We subsequently performed a prospective audit in 50 consecutive patients to determine the timing of NMB dosing and to quantify the incidence of residual paralysis after fast-track cardiac surgery. Of the 50 patients studied, 24 (48%) had received an NMB during the last hour of surgery and 33 (66%) had evidence of residual paralysis during the immediate postoperative period. Postoperative residual paralysis after fast-track cardiac surgery was common in our institution and likely contributed to the reported case of postoperative awake paralysis. We suggest that an NMB not be administered after intubation in fast-track patients. If given, however, it must be well communicated to the ICU team upon ICU admission. We further recommend routine assessment of neuromuscular function before sedation is weaned prior to extubation.
- 5 February 2016
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 63 (5) , 608-624
Medical cannabis: considerations for the anesthesiologist and pain physician
New regulations are in place at the federal and provincial levels in Canada regarding the way medical cannabis is to be controlled. We present them together with guidance for the safe use of medical cannabis and recent clinical trials on cannabis and pain. The new Canadian regulations on the use of medical cannabis, the provincial regulations, and the various cannabis products available from the Canadian Licensed Producers were reviewed from Health Canada, provincial licensing authorities, and the licensed producers website, respectively. Recent clinical trials on cannabis and pain were reviewed from the existing literature. Health Canada has approved a new regulation on medical marijuana/cannabis, the Marihuana for Medical Purposes Regulations: The production of medical cannabis by individuals is illegal. Health Canada, however, has licensed authorized producers across the country, limiting the production to specific licenses of certain cannabis products. There are currently 26 authorized licensed producers from seven Canadian provinces offering more than 200 strains of marijuana. We provide guidance for the safe use of medical cannabis. The recent literature indicates that currently available cannabinoids are modestly effective analgesics that provide a safe, reasonable therapeutic option for managing chronic non-cancer-related pain. The science of medical cannabis and the need for education of healthcare professionals and patients require continued effort. Although cannabinoids work to decrease pain, there is still a need to confirm these beneficial effects clinically and to exploit them with acceptable benefit-to-risk ratios.
- 5 February 2016
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 63 (5) , 608-624
Medical cannabis: considerations for the anesthesiologist and pain physician
New regulations are in place at the federal and provincial levels in Canada regarding the way medical cannabis is to be controlled. We present them together with guidance for the safe use of medical cannabis and recent clinical trials on cannabis and pain. The new Canadian regulations on the use of medical cannabis, the provincial regulations, and the various cannabis products available from the Canadian Licensed Producers were reviewed from Health Canada, provincial licensing authorities, and the licensed producers website, respectively. Recent clinical trials on cannabis and pain were reviewed from the existing literature. Health Canada has approved a new regulation on medical marijuana/cannabis, the Marihuana for Medical Purposes Regulations: The production of medical cannabis by individuals is illegal. Health Canada, however, has licensed authorized producers across the country, limiting the production to specific licenses of certain cannabis products. There are currently 26 authorized licensed producers from seven Canadian provinces offering more than 200 strains of marijuana. We provide guidance for the safe use of medical cannabis. The recent literature indicates that currently available cannabinoids are modestly effective analgesics that provide a safe, reasonable therapeutic option for managing chronic non-cancer-related pain. The science of medical cannabis and the need for education of healthcare professionals and patients require continued effort. Although cannabinoids work to decrease pain, there is still a need to confirm these beneficial effects clinically and to exploit them with acceptable benefit-to-risk ratios.